WORCESTER, Mass., July 25, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that the number of retail chains in Canada and the United States that are presently carrying its proprietary Glucose RapidSpray(tm) product has expanded. The latest addition to the retail chains have been a number of key online storefronts including www.Amazon.com and www.Walgreens.com; the first online storefront to carry the product was www.DiabeticExpress.com
Presently, Glucose RapidSpray (www.GlucoseRapidSpray.com) is being marketed in the United States and Canada through a number of leading retail chains. Amongst them are Amerimark Direct, Butler Drug Store, DIK Drug Co., Fruth Pharmacy, H.D. Smith Wholesale Drug, Hy-Vee Inc., Kerr Drug Inc., Kinney Drug, Inc., Kinray Inc., Meijer, Smith Drug Company, ShopKo, Weiss Markets Inc., Value Drug Company, RDC, Aurora Pharmacy, Amerisource Bergen, Bainder International Drug Stores, McKesson Drug Company, Cardinal Health Pharmacies, Amerisource Bergen, Kohl & Frisch Limited, Shoppers Drug Mart and UniPharm Wholesale Drugs Ltd.
Glucose RapidSpray is also being marketed in the Middle East through its Master Distributor Leosons General Trading Company.
Glucose RapidSpray is an innovative alternative for people who want additional glucose in their diet. The product delivers a fat-free, low-calorie glucose formulation directly into the buccal cavity using the Company's proprietary buccal drug delivery technologies. Glucose RapidSpray is simple to carry and use.
"We are pleased to expand the marketing and distribution of Glucose RapidSpray to additional retail chains with multiple locations," says Rose C. Perri, Generex's Chief Operating Officer. "We recognize the importance of the e-commerce market and we are pleased to have the opportunity to distribute within this marketplace as well. We look forward to exploring all of the commercial and marketing avenues available."
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and before the end of 2007 the Company expects to begin Phase 3 trials of the product in the United States, Canada and Europe. For more information, visit the Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.